| Literature DB >> 29104048 |
Wesley Jun1, Ran Hu2, Laura Hyland3, Darren Crandall4, Pradeep Ramachandran5, Chinmay Pangarkar6, Sharada Sivaraman7, Babak Haghiri8.
Abstract
Herpes simplex virus type-2 (HSV-2) specific glycoprotein G (gG-2) is widely used as the antigen of choice for serodiagnosis of HSV-2. In order to develop an ELISA for serodetection of HSV-2 IgG in patient sera, the soluble form of the mature gG-2 antigen (mgG-2), gG283-649, was expressed using a baculovirus expression system. gG283-649 contains the complete extracellular domain of mgG-2 including the C-terminal region, which despite homology to gG-1, does not cross-react with HSV-1 antibodies present in HSV-1 positive patient sera. gG283-649 had increased performance compared to a previously described gG-2 fragment and showed high sensitivity and specificity in a method comparison with HerpeSelect 1 & 2 Immunoblot IgG, a commercially available FDA-cleared assay for serodetection of HSV-1 and 2 antibodies. A total of 234 clinical samples consisting of 134 high risk samples, including 45 samples from pregnant subjects, and a panel of 100 mixed diagnosis samples, spanning the measurable range were tested in the method comparison. Clinical sensitivity and specificity were determined to be 94.2% and 100%, respectively. We conclude that this soluble form of mgG-2 is a novel antigen of choice for developing an ELISA for type-specific serodiagnosis of HSV-2.Entities:
Keywords: ELISA; Glycoprotein G; HSV-2; Serodiagnosis; gG-2
Mesh:
Substances:
Year: 2017 PMID: 29104048 DOI: 10.1016/j.jviromet.2017.10.021
Source DB: PubMed Journal: J Virol Methods ISSN: 0166-0934 Impact factor: 2.014